Back to top
more

Surgery Partners (SGRY)

(Delayed Data from NSDQ)

$28.75 USD

28.75
434,028

-0.05 (-0.17%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $28.75 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Better trading starts here.

Zacks News

Alignment Healthcare (ALHC) Reports Q3 Loss, Tops Revenue Estimates

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 0% and 4.50%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Surgery Partners (SGRY) Meets Q2 Earnings Estimates

Surgery Partners (SGRY) delivered earnings and revenue surprises of 0% and 3.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

SGRY or MEDP: Which Is the Better Value Stock Right Now?

SGRY vs. MEDP: Which Stock Is the Better Value Option?

SGRY vs. MEDP: Which Stock Is the Better Value Option?

SGRY vs. MEDP: Which Stock Is the Better Value Option?

Wall Street Analysts Think Surgery Partners (SGRY) Could Surge 57.53%: Read This Before Placing a Bet

The mean of analysts' price targets for Surgery Partners (SGRY) points to a 57.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Teladoc (TDOC) Soars 6.7%: Is Further Upside Left in the Stock?

Teladoc (TDOC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates

Surgery Partners (SGRY) delivered earnings and revenue surprises of 42.86% and 1.38%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

DocGo Inc. (DCGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Motion Acquisition (DCGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Surgery Partners (SGRY) Q1 Earnings Expected to Decline

Surgery Partners (SGRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?

SGRY vs. DOCS: Which Stock Is the Better Value Option?

Surgery Partners (SGRY) Upgraded to Buy: What Does It Mean for the Stock?

Surgery Partners (SGRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Surgery Partners (SGRY) Could Rally 39.04%: Here's is How to Trade

The mean of analysts' price targets for Surgery Partners (SGRY) points to a 39% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Company News for Feb 27, 2024

Companies in The News Are: DPZ,FRPT,SGRY,ITRI

The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Surgery Partners, Nvidia and Occidental Petroleum

Microsoft, Amazon.com, Surgery Partners, Nvidia and Occidental Petroleum are part of the Zacks top Analyst Blog.h

Sanghamitra Saha headshot

Warren Buffett's Annual Letter: Key Insights for Investors

Follow Warren Buffett's latest tips and bet on top-ranked stocks like Microsoft (MSFT), Amazon.com (AMZN), Surgery Partners (SGRY) and Nvidia (NVDA).

Here's What Key Metrics Tell Us About Surgery Partners (SGRY) Q4 Earnings

While the top- and bottom-line numbers for Surgery Partners (SGRY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Surgery Partners (SGRY) Beats Q4 Earnings Estimates

Surgery Partners (SGRY) delivered earnings and revenue surprises of 18.92% and 0.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Gear Up for Surgery Partners (SGRY) Q4 Earnings: Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Surgery Partners (SGRY) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

InnovAge Holding Corp. (INNV) Reports Q2 Loss, Tops Revenue Estimates

InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Surgery Partners (SGRY) is Poised to Beat Earnings Estimates Again

Surgery Partners (SGRY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Hologic's (HOLX) Q1 Earnings Beat Estimates, Gross Margin Down

Hologic's (HOLX) Breast Health segment registered strong growth in Q1, primarily owing to higher capital equipment revenues.

Will a Fall in Medicaid Customers Hurt Molina's (MOH) Q4 Earnings?

Molina Healthcare's (MOH) Q4 performance is likely to have been hurt by escalating medical care costs, and a decline in Medicaid and Marketplace membership, partly offset by growing Medicare premiums.

Boston Scientific (BSX) Q4 Earnings Top, Operating Margin Falls

Boston Scientific (BSX) sees an increase in organic and operational revenues in its core business segments and geographies in the reported quarter.

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.